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Abstract: Antisense oligodeoxynucleotides
(AS-ODNs) are short DNA sequences
synthesized complementary to the mRNA and
they inhibit the expression of the target gene
by forming a mRNA-DNA duplex. This
strategy can be considered to be an
alternative therapy for cancers characterized
by amplified oncogene activity.
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The purpose of this study was to evaluate the
inhibitory effect of AS-ODNs on two human
leukemia cell lines (HL-60 and K562). Cells
were treated with c-myb AS-ODNs at two
different concentrations and cell proliferation
was monitored on the 5th and 7th days of
culture. Sense and scrambled ODNs were used
as the control.
In both cell lines, AS-ODNs inhibited cell

Introduction

c-myb proto-oncogene is the cellular homolog of the
avian myeloblastosis virus transforming gene v-myb. Its
protein product c-myb is a transcription factor involved in
the regulation of hematopoietic cell proliferation and
differentiation (1,2). c-myb is highly expressed in
primitive hematopoietic cells, and its expression decreases
during maturation and differentiation. c-myb expression
is also elevated in some primary hematopoietic tumors
and in some leukemic cell lines (3,4). It has been shown
that enforced expression of c-myb can transform
preferentially myeloid lineage of hematopoietic cells, in
vitro and in vivo (5). Although many genes have been
identified likely to be regulated by c-myb, the critical
target genes are not known.
Methods of gene therapy in cancer depend on
different strategies (6). Some methods target the gene
itself (e.g. homologous recombination) and some target
the gene’s transcriptional product, the mRNA. Antisense
oligodeoxynucleotides (AS-ODNs) are short DNA
sequences 15-20 bp long, synthesized complementary to
the mRNA (7). Since ODNs are subject to degradation by

proliferation up to 90%, with inhibition being
more important at high ODN concentration. A
slight inhibition was also observed with sense
ODNs after 5 days of culture; but in contrast
with the AS-ODNs, this inhibition was
diminished in 7 days. Scrambled ODNs caused
a higher inhibition than sense ODNs.
This study shows that AS-ODNs, targeted to
an oncogene involved in cell proliferation,
inhibit malignant cell proliferation. The
inhibition observed with sense or scrambled
ODNs is due to non-sequence-specific ODN
binding. However, these non-specific effects
decrease at longer incubation times whereas
the antisense effect persists.
Key Words: Gene therapy, antisense
oligonucleotides, c-myb, leukemia

nucleases, they are chemically modified in order to
improve their stability. The most widely used one is the
phosphorothioate (PS) modification in which one of the
non-bridging oxygens of the internucleotide
phosphodiester linkages is replaced with sulfur (7). ASODNs form a duplex structure with mRNA and inhibit the
translation. In addition, the destruction of the mRNA by
RNAse H is promoted (8). It has been proposed that ASODNs might have an antiproliferative effect through the
stepwise release of deoxyribonucleotides under the effect
of exonucleases (9). Therefore, targeting an oncogene
with AS-ODNs is a way of inhibiting oncogene expression
and this can be an alternative strategy to control the
growth of cancers with amplified oncogene activity (10).
In this study, HL-60 human acute promyelocytic
leukemia cells and K562 human chronic myelogenous
leukemia cells were treated with c-myb AS-ODNs. Nontreated cells and sense ODN (S-ODN)- or scrambled ODN
(Scr-ODN)-treated cells were used as controls. Our aim
was not only to evaluate the effect of AS-ODNs on
malignant cell proliferation in vitro, but also to evaluate
the specificity of the antisense effect.

* Present address: James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
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Materials and Methods

Results

Cell Lines and Culture. HL-60 human acute
promyelocytic leukemia cell line and K562 human chronic
myelogenous leukemia cell line were obtained from the
American Type Culture Collection. Cells were maintained
in RPMI-1640 medium supplemented with 10% heatinactivated bovine calf serum, 2 mM glutamine and
antibiotics. Cells were incubated at 37 ºC in a 5% CO295% air mixture.

1. Effect of c-myb AS-ODNs on the proliferation of
HL-60 cells. The effect of c-myb AS-ODNs and S-ODNs
on HL-60 cell growth rate is shown in Figure 1. Cells
were counted on the 5th and 7th days of culture, and
oligonucleotide-treated cells were compared to nontreated (control) cells. After 5 days of incubation with ASODNs, cell growth was inhibited to 88.5% with low dose
(40 µg/ml) and 91% with high dose (100 µg/ml)
oligonucleotides. For the same period of incubation, the
inhibition was 19.8% with low dose S-ODNs and 31.1%
with high dose S-ODNs. When the incubation period was
prolonged to 7 days, the inhibition of cell proliferation
was less prominent but was still over 60% for both low
and high doses of AS-ODNs. In fact, no more cell
proliferation was observed in control cells after 7 days of
culture and S-ODNs had very little effect on cell
proliferation: 5.5% at low dose and 2.8% at high dose.

Oligodeoxynucleotides. PS-ODNs corresponding to cmyb codons 2-7 were prepared on an automated
synthesis instrument in the Nucleic Acid Facility of the
Department of Chemistry, University of Pennsylvania
Cancer Center. The sense sequence was 5’-GCC CGA AGA
CCC CGG CAC-3’, the antisense sequence was 5’-GTG
CCG GGG TCT TCG GGC-3’, and the scrambled sequence
was 5’-CGC GCG TGT GGC GTC GGT-3’.
Determination of the Cell Proliferation Rate. Cells
were resuspended in fresh medium containing serum and
seeded in 96-well plates at a density of 500 cells per well
in a volume of 200 µl. ODNs were prepared in medium
without serum and added to cells at two different
concentrations: 40 µg/ml (8 µg/well) and 100 µg/ml (20
µg/well). Cells were counted on the 5th and 7th days of
culture using a hemacytometer. All experiments were
performed at least in quadruplicate. Results are
expressed as mean ± SD. A two tailed t-test was used for
statistical analysis and P < 0.001 was considered
significant.
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2. Effect of c-myb AS-ODNs on the proliferation of
K562 cells. The effect of c-myb AS-ODNs on K562 cell
growth rate is shown in Figure 2. The normal growth
rate of K562 cells was less than that of HL-60 cells. After
5 days of culture, there were 637.5 ± 14.47 x 103 K562
cells per ml whereas there were 1208.75 ± 102.25 x 103
HL-60 cells per ml of culture medium. On the 5th day of
culture there was a 78% inhibition with low dose and
87.4% inhibition with high dose c-myb AS-ODNs.
Inhibition with S-ODNs for the same period of time was
3.3% for low dose and 26.4% for high dose
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Effect of c-myb AS-ODNs on the proliferation of HL-60
cells. The concentration of low dose ODNs is 40 mg/ml and
that of high dose ODNs is 100 mg/ml. The results are
expressed as mean ± SD of at least quadruple cell counts.
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Effect of c-myb AS-ODNs on the proliferation of K562 cells.
The concentration of low dose ODNs is 40 mg/ml and that
of high dose ODNs is 100 mg/ml. The results are expressed
as mean ± SD of at least quadruple cell counts.
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oligonucleotides. In contrast with HL-60 cells, K562 cells
were still proliferating after 7 days of culture. There were
820 ± 36.4 x 103 cells per ml. The inhibition of cell
growth was again less prominent with AS-ODNs at 7
days: 41.6% at low dose and 87.9% at high dose. For
the same period, there was practically no inhibition with
S-ODNs: 0.23% at low dose and 0% at high dose.
3. Effect of Scr-ODNs on the proliferation of HL-60
and K562 cells. Scr-ODNs also inhibited cell proliferation
in both cell lines (Table). The inhibitory effect of Scr-ODNs
was close to the effect of AS-ODNs after 5 days of
incubation. On the 7th day, inhibition was less prominent in
HL-60 cells, but in K562 cells the degree of inhibition was
approximately the same as that obtained with AS-ODNs.

Discussion
In this study, we compared the effect of c-myb ASODNs on the proliferation of two leukemia cell lines, HL60 and K562, by varying both ODN concentrations and
the time of incubation. We also used sense and scrambled
sequences to evaluate the specificity of the antisense
effect. HL-60 cells have been widely used in antisense
research, but very few studies have been done concerning
antisense effect on K562 cells, and there is no
comparative study. We found that the proliferation of
both cell lines was significantly inhibited by c-myb ASODNs regardless of the ODN concentration. The fact that
there were more cells than seeded indicated that there
was no direct cytotoxic effect of ODNs and that they in
fact had an inhibitory effect on proliferation. The
proliferation rate of K562 cells was lower than that of
HL-60 cells, which facilitated the observation of timedependent effects. After 5 days of incubation, the
inhibitory effect of high dose AS-ODNs was slightly higher
than that of low dose AS-ODNs, but it was not
proportional to the dose increase. The difference between
Table.

the effects of low and high doses was more prominent at
7 days. Apparently, higher doses of AS-ODNs are more
effective in inhibiting proliferation at longer incubation
times, probably because higher ODN concentrations are
necessary to overcome accumulating proliferative signals.
We observed less or no inhibition with S-ODNs, which
indicated a more specific inhibitory effect for AS-ODNs.
However, Scr-ODNs also showed an inhibitory effect on
the proliferation of both cell lines. The interaction of
ODNs with other molecules (especially positively charged
ones) is a critical problem concerning the specificity of ASODNs (11). PS-ODNs show increased avidity in binding to
proteins when compared to their phosphodiester
counterparts (12). In our study, PS structure should not
be the cause of the non-specific effect, because S-ODNs
showed no or very little inhibition. It is more likely that
Scr-ODNs might be involved in aptamer formation, which
means a sequence-specific interaction of ODNs with a
protein (13). Aptamer strategy is considered to have
potential therapeutic use in some pathologies and this
type of interaction can explain the differential effects of
S- and Scr-ODNs in our experiments (14).
The presence of a G-quartet gives the oligonucleotide
the ability to self-aggregate via the formation of G-G
Hoogsteen pairs. The G-quartet motif is thought to be
implicated in non-sequence-specific effects although the
mechanism is not fully explained (15). The Scr-ODN that
we used did not contain any G-quartet whereas the ASODN does. Therefore, the inhibitory effect of Scr-ODNs
cannot be explained by the presence of a G-quartet.
Moreover, G-quartet-containing AS-ODNs have been
widely used in antisense studies and even in clinical trials.
Several precautions can be taken in order to improve
the specificity of the antisense effect. The length of the
oligonucleotide should be in the range of 16-20
nucleotides and the oligonucleotide concentration should

Effect of Scr-ODNs on the proliferation of HL-60 and K562 cells.
HL-60

K562

5 days

7 days

5 days

7 days

1208,75 ± 102,25

1153,75 ± 56,94

637,50 ± 14,47

820,00 ± 36,44

Scr-ODN low dose

150,63 ± 57,46

696,88 ± 30,69

208,75 ± 45,05

355,63 ± 11,23

Scr-ODN high dose

88,75 ± 8,00

347,50 ± 39,61

88,13 ± 16,14

105,63 ± 8,36

Control

The results are given as mean ± SD of the cell count x1000/ml of culture medium.
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be kept low (not more than 4-5 µM) (16). Our ODNs
were 18 nucleotides long and we used them at 6.5 and
13 µM concentration. We delivered the ODNs without a
carrier (also called naked) and it is well known that higher
concentrations of naked oligonucleotides are required to
obtain antisense effect. Unfortunately, non-sequencespecific effects are more commonly produced at such
concentrations (16). Using cationic lipids or polyamines as
a carrier can facilitate delivery and minimize nonsequence-specific effects by neutralizing negative charges
on the oligonucleotides (17-19).
Studies on antisense ODNs has been going on for
more than 20 years and the method has faced a number
of complex challenges. Several companies have developed
antisense drugs that are successfully used in clinical trials,

while experiments are going on to improve the
methodology (20). Although the development of
antisense methods is difficult and expensive, antisense
drugs are still promising.
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